Loading organizations...
§ Private Profile · Lexington, MA, USA
Biotech company developing cancer immunotherapies using monoclonal antibodies and fungal carbohydrates for oncology patients.
ImmuneXcite, based in Lexington, Massachusetts, develops cancer immunotherapies by chemically linking fungal carbohydrates to FDA-approved monoclonal antibodies, such as trastuzumab and cetuximab, to attract neutrophils to tumor sites and enable the immune system to attack cancer cells. The venture-backed biotech company has secured over $20 million in total funding, including an $8.6 million Series A round and a $3.58 million Series B round, with support from government sources like the National Cancer Institute. Lead investors include Cormorant Asset Management, Sanofi Genzyme BioVentures, and Partners Innovation Fund. The company expanded its leadership and board with industry veterans such as Executive Chairman John Edwards, formerly of Genzyme, and CEO Eric Furfine. ImmuneXcite, initially focusing on breast and colorectal cancers, was founded in 2007 by Ifat Rubin-Bejerano and Yaniv Bejerano.
ImmuneXcite has raised $12.2M across 2 funding rounds.
ImmuneXcite has raised $12.2M in total across 2 funding rounds.
ImmuneXcite has raised $12.2M across 2 funding rounds. Most recently, it raised $8.6M Series A in March 2016.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 30, 2016 | $8.6M Series A | — | Cormorant Asset Management, Partners Innovation Fund, ANN Dewitt | Announced |
| Jan 8, 2014 | $3.6M Series B | — | — | Announced |
ImmuneXcite has raised $12.2M in total across 2 funding rounds.
ImmuneXcite's investors include Cormorant Asset Management, Partners Innovation Fund, Ann DeWitt.